Leukemia inhibitory factor ameliorates experimental anti-GBM Ab glomerulonephritis

Area of Science:

• Nephrology
• Immunology
• Molecular Biology

Background:

• Leukemia inhibitory factor (LIF) is a cytokine implicated in inflammatory conditions.
• Its role in anti-glomerular basement membrane (anti-GBM) antibody-induced glomerulonephritis (GN) was previously unclear.

Purpose of the Study:

• To investigate glomerular LIF expression following anti-GBM antibody administration.
• To evaluate the therapeutic effect of recombinant human LIF (rhLIF) in a rat model of anti-GBM GN.

Main Methods:

• RNase protection assay was used to measure LIF mRNA in glomeruli at various time points post-anti-GBM antibody induction.
• Cultured rat mesangial cells were stimulated with IL-1 beta to assess LIF production.
• Lewis rats were infused with rhLIF or saline before and during anti-GBM antibody injection.
• Urinary protein excretion, glomerular macrophage infiltration, and cytokine mRNA expression were analyzed.

Main Results:

• LIF mRNA expression significantly increased in glomeruli after anti-GBM antibody induction, with mesangial cells identified as a potential source.
• rhLIF infusion markedly reduced 24-hour urinary protein excretion by 85% and glomerular macrophage infiltration by 60%.
• rhLIF administration led to decreased glomerular expression of MCP-1, IL-1, and TNF mRNA, and reduced TNF-alpha protein levels.

Conclusions:

• LIF expression is upregulated in anti-GBM antibody GN.
• rhLIF exerts protective effects by reducing proteinuria and inflammation.
• LIF represents a potential therapeutic target for anti-GBM antibody GN.